(19)
(11) EP 2 512 242 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.12.2015 Bulletin 2015/50

(45) Mention of the grant of the patent:
30.09.2015 Bulletin 2015/40

(21) Application number: 10838240.9

(22) Date of filing: 16.12.2010
(51) International Patent Classification (IPC): 
C07D 495/04(2006.01)
A61P 25/28(2006.01)
 A61K 31/4365(2006.01)
(86) International application number:
PCT/US2010/060696
(87) International publication number:
WO 2011/075559 (23.06.2011 Gazette 2011/25)

(54)

NOVEL COMPOUNDS

NEUARTIGE VERBINDUNGEN

NOUVEAUX COMPOSÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.12.2009 US 287798 P

(43) Date of publication of application:
24.10.2012 Bulletin 2012/43

(73) Proprietor: GlaxoSmithKline Intellectual Property Limited
Brentford, Middlesex TW8 9GS (GB)

(72) Inventors:
  • CHEN, Deborah
    Commonwealth 138667 (SG)
  • LEE, Kiew, Ching
    Commonwealth 138667 (SG)
  • TERRELL, Lamont, Roscoe
    PA 19406 (US)

(74) Representative: Drury, Elizabeth Anne 
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
EP-A1- 1 505 068
US-A1- 2007 082 880
 EP-A1- 1 598 354
   
  • XU ET AL: 'Catalytic Domain Crystal Structure of Protein Kinase C-theta' JBC vol. 279, no. 48, 26 November 2004, pages 50401 - 50409, XP002376549
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).